Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive dahl rats

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Geschka, Sandra ^a   Kretschmer, Axel ^b   Sharkovska, Yuliya ^c,d   Evgenov, Oleg V ^e   Lawrenz, Bettina ^f   Hucke, Andreas ^a   Hocher, Berthold ^c,d   Stasch, Johannes Peter ^a,g  

^a Cardiology Research   (Germany)

^b Bayer HealthCare   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f Pathology   (Germany)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GUANYLATE CYCLASE; MESSENGER RNA; OSTEOPONTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RIOCIGUAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; CELL RECEPTOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SOLUBLE GUANYLYL CYCLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DOSE RESPONSE; DRUG DOSE COMPARISON; ENZYME ACTIVATION; FIBROGENESIS; GENE; GENE EXPRESSION REGULATION; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; KIDNEY HYPERTROPHY; MALE; MALIGNANT HYPERTENSION; NONHUMAN; OSTEOPONTIN GENE; OUTCOME ASSESSMENT; PLASMINOGEN ACTIVATOR INHIBITOR 1 GENE; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RAT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; TISSUE DEGENERATION; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD; BLOOD PRESSURE; BODY WEIGHT; DRUG EFFECT; ECHOCARDIOGRAPHY; FIBROSIS; GENETICS; HEART MUSCLE; HEART RATE; HEMODYNAMICS; KIDNEY; KIDNEY FUNCTION TEST; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; SYSTOLE; URINE;

RATTUS; RODENTIA;

ANIMALS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY WEIGHT; ECHOCARDIOGRAPHY; FIBROSIS; GENE EXPRESSION REGULATION; GUANYLATE CYCLASE; HEART RATE; HEMODYNAMICS; KIDNEY; KIDNEY FUNCTION TESTS; MYOCARDIUM; ORGAN SIZE; ORGAN SPECIFICITY; PYRAZOLES; PYRIMIDINES; RATS; RATS, INBRED DAHL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SURVIVAL ANALYSIS; SYSTOLE;

EID: 79960599350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021853     Document Type: Article

References (40)

1. Carey RM, eds. (2007) Angiotensin II and Inflammation, in Hypertension and Hormone Mechanisms, Contemporary Endocrinology pp. 91-110.
2. Perco P, Wilflingseder J, Bernthaler A, Wiesinger M, Rudnicki M, et al. (2008) Biomarker candidates for cardiovascular disease and bone metabolism disorders in chronic kidney disease: a systems biology perspective. J Cell Mol Med 44: 1177-1187.
3. Waller AH, Sanchez-Ross M, Kaluski E, Klapholz M, (2010) Osteopontin in Cardiovascular Disease. Cardiology 18: 125-131.
4. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, et al. (2008) Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure. Circ Heart Fail 1: 43-49.
5. Lorenzen JM, Nickel N, Krämer R, Golpon H, Westerkamp V, et al. (2011) Osteopontin in patients with idiopathic pulmonary hypertension. Chest 139: 1010-7.
6. Lorenzen J, Krämer R, Kliem V, Bode-Boeger SM, Veldink H, et al. (2010) Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest 40: 294-300.
7. Ha H, Oh EY, Lee HB, (2009) The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases. Nat Rev Nephrol 5: 203-211.
8. Arikan H, Koc M, Sari H, Tuglular S, Ozener C, et al. (2007) Associations between Apolipoprotein E Gene Polymorphism and Plasminogen Activator Inhibitor-1 and Atherogenic Lipid Profile in Dialysis Patients. Ren Fail 29: 713-719.
9. Josepha J, Pencina MJ, Wang TJ, Hayes L, Tofler GH, et al. (2009) Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. J Hypertens 27: 1317-1324.
10. Frantz S, Störk S, Michels K, Eigenthaler M, Ertl G, et al. (2008) Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur J Heart Fail 10: 388-395.
11. Mittendorf J, Weigand S, Alonso-Alija C, Bischoff E, Feurer A, et al. (2009) Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 4: 853-865.
12. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, et al. (2006) NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768.
13. Stasch JP, Pacher P, Evgenov OV, Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation Epub 2011 May 23.
14. Schermuly R, Stasch JP, Pullamsetti SS, Middendorff R, Mueller D, et al. (2008) Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 32: 881-891.
15. Sharkovska Y, Kalk P, Lawrenz B, Godes M, Hoffmann LS, et al. (2010) Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens 28: 1666-1675.
16. Stasch JP, Hobbs AJ, (2009) NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol (2009) pp. 277-308.
17. Pacher P, Beckman JS, Liaudet L, (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87: 315-424.
18. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, et al. (2009) First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 33: 785-792.
19. Kim NH, (2010) Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Eur Respir Rev 19: 68-71.
20. Ghofrani HA, Hoeper MM, Halank M, Meyer FJ, Staehler G, et al. (2010) Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 36: 792-729.
21. Stasch JP, Kazda S, Hirth-Dietrich C, Neuser D, (1990) Effects of nisoldipine on atrial natriuretic peptides, blood pressure and cardiac hypertrophy in Dahl rats. Clin Exptl Hypertens A12: 1419-1436.
22. Stasch JP, Knorr A, Hirth-Dietrich C, Krämer T, Hübsch W, et al. (1997) Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. Arzneimittel-forschung 47: 1016-1023.
23. Manning RD Jr, Meng S, Tian N, (2003) Renal and vascular oxidative stress and salt-sensitivity of arterial pressure. Acta Physiol Scand 179: 243-250.
24. Manning RD Jr, Tian N, Meng S, (2005) Oxidative stress and antioxidant treatment in hypertension and the associated renal damage. Am J Nephrol 25: 311-317.
25. Majid DS, Kopkan L, (2007) Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension. Clin Exp Pharmacol Physiol 34: 946-952.
26. St Lezin E, Simonet L, Pravenec M, Kurtz TW, (1992) Hypertensive strains and normotensive 'control' strains. How closely are they related? Hypertension 19: 419-424.
27. Chen PY, Sanders PW, (1991) L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 88: 1559-1567.
28. Wang Y, Krämer S, Loof T, Martini S, Kron S, et al. (2006) Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am J Physiol Renal Physiol 290: F167-176.
29. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, et al. (2009) Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 32: 597-603.
30. Johnson RJ, Gordon KL, Giachelli C, Terry K, Skelton MM, et al. (2000) Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-SS Rat. J Hypertens 18: 1497-1505.
31. Brown L, Chan V, Fenning A, (2005) Interstitial Fibrosis in Heart Failure; Targets for Pharmacological Modulation of Cardiac Fibrosis. Developments in Cardiovascular Medicine 253: 275-310.
32. Chen PY, St John PL, Kirk KA, Abrahamson DR, Sanders PW, (1993) Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 68: 174-184.
33. Tamaki K, Okuda S, Nakayama M, Yanagida T, Fujishima M, (1996) Transforming growth factor-beta 1 in hypertensive renal injury in Dahl salt-sensitive rats. J Am Soc Nephrol 7: 2578-2589.
34. Chandramohan G, Bai Y, Norris K, Rodriguez-Iturbe B, Vaziri ND, (2008) Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and-resistant rat kidneys. Am J Nephrol 28: 158-167.
35. Schwarz ER, Pollick C, Meehan WP, Kloner RA, (1998) Evaluation of cardiac structures and function in small experimental animals: Transthoracic, transesophageal and intraventricular echocardiographie to assess contractile function in rat heart. Basic Res Cardiol 93: 477-486.
36. Haffner D, Hocher B, Muller D, Simon K, Konig K, et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067-1075.
37. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. (2002) Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135: 333-343.
38. Stasch JP, Knorr A, Hirth-Dietrich C, Krämer T, Hübsch W, et al. (1997) Long-term blockade of the angiotensin II receptor in renin transgenic rats, salt-loaded Dahl rats, and stroke-prone spontaneously hypertensive rats. Arzneimittel-forschung 47: 1016-1023.
39. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, et al. (1999) Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 33: 816-822.
40. Hocher B, George I, Diekmann F, Zart R, Rebstock J, et al. (2000) ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 18: 1807-1814.